Modality
Cell Therapy
MOA
KRASG12Ci
Target
B7-H3
Pathway
Notch
HS
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
Jan 2019
→ May 2027
Phase 1Current
NCT08431039
1,352 pts·HS
2019-01→TBD·Recruiting
NCT06226102
2,569 pts·HS
2019-03→2027-05·Active
3,921 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-05-251.1y awayInterim· HS
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Recruit…
P1
Active
Catalysts
Interim
2027-05-25 · 1.1y away
HS
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08431039 | Phase 1 | HS | Recruiting | 1352 | HbA1c |
| NCT06226102 | Phase 1 | HS | Active | 2569 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 |